“Buzz on the Street” Show: Amarantus Bioscience (OTC: AMBS) Eltoprazine & CBD to Treat Parkinson’s – Financialbuzz.com

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease.”

Amarantus Bioscience Holdings, Inc. (OTC: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that subsidiary Elto Pharma, Inc. has received a notice of allowance from the European Patent Office (EPO) covering the use of eltoprazine and eltoprazine in combination with a number of chemical compounds, including cannabidiol (CBD) in the treatment of Parkinson’s disease and Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Once issued, the patent will protect the use of eltoprazine in the treatment of Parkinson’s and PD-LID through 2034. Elto Pharma is focused on the development of eltoprazine as an oral formulation for the treatment of PD-LID, Adult ADHD and Agitation in Alzheimer’s disease.

Amarantus Bioscience Holdings is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical, Ltd. has licensed intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test ® from Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis diagnostic MSPrecise™ and Parkinson’s diagnostic NuroPro. Amarantus entered into a joint venture agreement with Todos Medical, Ltd. to advance diagnostic screening assets, and Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 50% ownership of Todos. The transaction is expected close before the end of the first quarter of 2020. Amarantus also owns approximately 30% of the common shares of Avant Diagnostics, Inc., a healthcare data-generating technology company that specializes in biomarker assay services that target multiple areas of oncology.  Avant provides precision oncology data through its TheraLink® assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders, initially for breast cancer, to over 70 FDA-approved drug treatments.

Over the past year, demand for cannabidiol, or CBD, has been increasing at an exponential pace. In particular, the U.S. experienced massive growth in CBD sales after it passed the Farm Bill in late 2018, legalizing the commercialization of hemp, which CBD is derived from. CBD is the active chemical found within the hemp plant, which falls under the cannabis family. Similarly, marijuana also falls under the cannabis family, but marijuana and hemp are widely different in their biological makeup, as marijuana’s active chemical is THC, which is generally known to induce psychoactive effects. Meanwhile, CBD does not cause mind-altering effects but instead stimulates relaxation. Moreover, extensive clinical trials have also concluded that CBD can be effectively used in healthcare to treat a variety of medical conditions. Consequently, many countries began to move towards legalizing CBD because of its versatile uses. For instance, researchers have boasted that CBD can treat symptoms associated with cancer, chronic pain, Alzheimer’s, multiple sclerosis, and epilepsy. However, in the U.S., there is currently only one CBD-based drug approved: Epidiolex. Epidiolex is used to treat Lennox-Gastaut and Dravet syndromes, which are two rare epileptic disorders that occur early in adolescence. And while the U.S. has only approved CBD for epilepsy-related conditions, other countries have legalized CBD-based drugs to treat other serious conditions such as HIV/AIDS, depression, and even withdrawal from opioid drugs. Nevertheless, it is important to remember that the CBD industry is still in its infancy stage due to the lack of research authenticating the benefits of the compound. But researchers around the world are engaged in clinical trials to rectify this and prove the efficacy of CBD while promoting it as a next-generation medical treatment. According to data compiled by Grand View Research, the global cannabidiol market was valued at USD 1.34 Billion in 2018 and is expected to expand at a CAGR of 32.6% over the forecast period from 2019 to 2025. 

Overall, there are hundreds of studies being conducted to evaluate the efficacy of CBD. Notably, researchers are advancing studies to further promote the use of the CBD for Parkinson’s treatment. Currently, the research on CBD for Parkinson’s is very limited and most studies are likely small-scale trials. However, the handful of studies that have been conducted suggest that CBD can have positive effects when dealing with nonmotor symptoms. According to Healthline, several studies have hinted that CBD can be used to treat tremors, psychosis, and improve the overall quality of life for some patients. For example, a small scale study suggested that CBD may help ease muscle movements, while another study discovered that CBD reduced the severity of individuals’ suffering from psychotic symptoms. Meanwhile, another study suggested that CBD can help suppress sleep disturbances such as vivid dreams, nightmares, or movement. Additionally, several researchers even believe that CBD can ultimately be used to prevent Parkinson’s disease, even as there is currently insufficient data on the use of CBD on humans to prevent Parkinson’s. Nevertheless, researchers are actively evaluating the effects of CBD on protecting the human brain. And while research on CBD is limited, the small-scale results are highly promising. As such, CBD clinical trials are anticipated to accelerate in the shortcoming future. “The work to date on marijuana and cannabinoids has given promising but conflicting signals,” said Rachel Dolhun, MD, Vice President, Medical Communications at The Michael J. Fox Foundation for Parkinson’s Research. “This therapy may represent a future treatment option for PD, but the correct dose and formulation are not clear, full side effects and drug interactions are unknown, and benefits have not been rigorously determined. Future studies should be large and well designed to provide clear data on the safety and efficacy of marijuana and cannabinoids in Parkinson’s.”

For more information, please visit: Amarantus Bioscience Holdings, Inc.

For more corporate news on Amarantus Bioscience Holdings, Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

Source: https://www.financialbuzz.com/buzz-on-the-street-show-amarantus-bioscience-otc-ambs-eltoprazine-cbd-to-treat-parkinsons/